Article

A Novel FLT3 Y842D Mutation Carriers a Potentially Highly Sensitivity to Midostaurin? Case Report and Literature Review

2021-02-15

Abstract excerpt

<h4>Background: </h4> Y842D mutation in the activation loop of FLT3 caused a strong resistance to Sorafenib in vitro, whether this kind of mutation would exert clinical significance on acute myeloid leukemia (AML) patients remain to be clarified. Case presentation: Here, we described a novel type of activating mutation (Y842D) within the kinase domain of FLT3 in a pregnancy with de novo acute myeloid leukemia. Fol...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 84e417e6-f54f-58ec-b4ad-9a7cb0726ea9
DOI: 10.21203/rs.3.rs-197301/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A Novel FLT3 Y842D Mutation Carriers a Potentially Highly Sensitivity to Midostaurin? Case Report and Literature ReviewDOI 10.21203/rs.3.rs-197301/v1Read

The FLT3 Y842D mutation may be highly sensitive to midostaurin: a case report.Semantic proximity Read

Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.Semantic proximity Read

Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin.Semantic proximity Read

CLINICAL FEATURES OF FLT3 MUTATIONS IN ACUTE MYELOID LEUKEMIA CASES AND THE ROLE OF FLT3 INHIBITORS IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA: A SINGLE CENTER EXPERIENCESemantic proximity Read

Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.Semantic proximity Read

Identification of a novel mutation of the FLT3 gene located on the juxtamembrane domain from acute myeloid leukemia patients.Semantic proximity Read

Isavuconazole therapy in an FLT3 mutated acute myeloid leukemia patient receiving midostaurin: A case report.Semantic proximity Read

Clinical and molecular response of AML harboring non-canonical <i>FLT3</i> N676K driver mutations to contemporary FLT3 inhibitorsSemantic proximity Read

Midostaurin approved for FLT3-mutated AML.Semantic proximity Read

Updated safety of midostaurin plus chemotherapy in newly diagnosed FLT3 mutation-positive acute myeloid leukemia: the RADIUS-X expanded access program.Semantic proximity Read

Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis.Semantic proximity Read

[Research Progress on Treating Acute Myeloid Leukemia by Midostaurin].Semantic proximity Read